Results: The pCR rate was 15% [95% confidence interval (CI) 7-28] in 53 patients receiving XT and 40% (95% CI 26-55) in 50 patients receiving HXT. After neoadjuvant therapy, 50 patients receiving XT and 45 receiving HXT underwent surgery. No unexpected toxicity was observed: the most common grade ‡3 adverse events were diarrhea/mucositis (30% and 20%, respectively) and grade 3 hand-foot syndrome (11% and 6%, respectively). Disease-free survival and overall survival were similar with XT and HXT after median follow-up of 22 months in the XT cohort and 21 months in the HXT cohort.
introduction Primary systemic chemotherapy is the preferred approach for the management of early breast cancer if breast-conserving surgery is not possible [1] or in patients with large tumors in whom breast-conserving surgery is desired. Most patients in neoadjuvant chemotherapy trials are typically in the latter category. For example, in the ABCSG-24 trial, 75% of patients had tumors <5 cm in diameter and only 4% had T4 tumors [2] . Neoadjuvant trials including only inoperable locally advanced tumors are rare.
Pathologic complete response (pCR) is generally accepted as a relevant outcome measure for neoadjuvant chemotherapy, significantly predicting overall survival [3, 4] . In high-risk early breast cancer, the inclusion of a taxane in neoadjuvant regimens significantly improves outcomes, as demonstrated in the B-27 and ECTO trials [3, 5] . Consequently, in patients at high risk of relapse, taxane-containing therapy is widely used. In patients with human epidermal growth factor receptor 2 (HER2)-positive disease, trastuzumab is a standard of care. Anthracyclines are standard of care in neoadjuvant chemotherapy regimens but increase the long-term risk of cardiac failure [6] . In the era of trastuzumab, which is also associated with cardiac effects, it may be relevant to investigate nonanthracycline neoadjuvant chemotherapy regimens and to evaluate the impact of adding trastuzumab in patients with HER2-positive tumors.
Docetaxel and capecitabine have demonstrated high activity in metastatic breast cancer (MBC), either alone or in combination. The capecitabine-docetaxel combination (XT) significantly improves efficacy compared with docetaxel alone in anthracycline-pretreated MBC [7] and more recently has shown high activity as first-line therapy for HER2-negative and HER2-positive MBC [8] [9] [10] [11] .
In early breast cancer, two recent phase III trials (FinXX and ABCSG-24) have shown significantly improved outcomes when capecitabine is integrated into adjuvant and neoadjuvant anthracycline-and taxane-containing regimens [2, 12] . Although these data were not available at the time the present trial was initiated, data from a randomized phase III trial in the neoadjuvant setting demonstrated significantly higher pCR rate with XT compared with doxorubicin-cyclophosphamide therapy [13] . In addition, several single-arm studies showed promising activity of neoadjuvant XT [14] [15] [16] [17] [18] [19] [20] . One of these trials, XeNA, investigated XT with trastuzumab (HXT) in HER2-positive tumors [16] .
Our study aimed to evaluate the XT combination (HXT in HER2-positive disease) in patients with inoperable cT4 or N2 or N3 locally advanced breast cancer (LABC). Few studies focus specifically on this difficult-to-treat patient population. The design also allowed evaluation of the effect of adding trastuzumab in the HER2-positive cohort compared with XT alone in the HER2-negative cohort.
patients and methods
The primary objective of this prospective, open-label, multicenter, nonrandomized study was to evaluate the feasibility and activity of neoadjuvant XT and HXT in patients with ineligible LABC.
eligibility
The main inclusion criteria were: female with histologically proven invasive LABC (cT4 with any N stage or N2 or N3 with any T stage according to the American Joint Committee on Cancer staging); World Health Organization performance status 0-2; age ‡18 years; and adequate bone marrow, hepatic, renal, and cardiac function. After the adjuvant data on trastuzumab became available, an amendment was made on 4 April 2005 to allow trastuzumab in patients with HER2-positive tumors, defined as immunohistochemistry (IHC) either 3+, or 2+ confirmed by a positive fluorescence in situ hybridization (FISH) score. Following a second protocol amendment on 25 September 2006, HER2 positivity was to be demonstrated by FISH in all patients. Patients were excluded if they were pregnant or breast-feeding or had: distant metastasis, including bone metastasis; received previous chemotherapy or radiation therapy; lack of integrity of the upper gastrointestinal tract, malabsorption syndrome, or inflammatory bowel disease; or clinically significant cardiac disease.
All patients provided written informed consent according to ICH/EU Good Clinical Practice guidelines, the Declaration of Helsinki, and local regulations before study enrollment. The study design and conduct were approved by the institutional ethics committee.
treatment schedule
Patients received up to six 21-day cycles of capecitabine 900 mg/m 2 twice daily, days 1-14, plus docetaxel 36 mg/m 2 as a 1-h infusion on days 1 and 8. A protocol-specified reduction of the capecitabine starting dose to 675 mg/m 2 twice daily was recommended in patients aged ‡60 years. We selected this regimen based on data showing high efficacy of low-dose weekly docetaxel in the neoadjuvant setting [21] and our own experience [22] . Preliminary results of a study evaluating docetaxel 30 mg/m 2 weekly in combination with capecitabine 900 mg/m 2 suggested that this regimen was feasible with good activity [23] . However, updated results [24] indicated that the cumulative nail toxicity might be problematic. Therefore, we selected a slightly adapted schedule, with docetaxel given at 36 mg/m 2 on days 1 and 8 combined with oral capecitabine given at 900 mg/m 2 b.i.d. on days 1-14 every 3 weeks.
Treatment was discontinued in patients with disease progression or unacceptable toxicity. Patients with HER2-positive tumors (as defined above) received trastuzumab every 3 weeks with chemotherapy in the neoadjuvant setting and alone in the adjuvant setting for a total duration of 1 year. Standard dose-modification schemes, including both treatment interruption and dose reduction, were implemented for all agents. Prophylactic granulocyte colony-stimulating factor was not permitted during the study. After completion of chemotherapy, locoregional treatment was agreed during a multidisciplinary consultation with surgeons and radiotherapists. Surgery was carried out between 1 and 3 weeks after the last capecitabine administration. Postoperative treatment was at the discretion of the investigator. Adjuvant endocrine therapy was mandatory in patients with hormone receptor-positive tumors.
study assessments
Baseline assessments included medical history, clinical examination, measurement of disease parameters, blood counts, and serum chemistry within 21 days before treatment start. Clinical examination and serum chemistry assessments were carried out immediately before the start of each cycle. Complete blood counts were carried out on days 1 and 8 of each cycle. Clinical response and adverse events were recorded after each cycle of chemotherapy. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria (version 2.0). Cardiac safety was assessed using multigated acquisition scan or echocardiography according to institution standard guidelines for the follow-up of patients receiving trastuzumab. After the third and sixth cycles of therapy, primary tumor response was evaluated using the most appropriate imaging technique (ultrasound, mammography, and/or computed tomography scan). The same imaging technique was used for all assessments. Clinical response was defined as a >30% decrease in the largest tumor diameter (RECIST). Patients with a tumor response or stable disease after the third cycle received a further three cycles of therapy.
biomarker substudy
In a biomarker study in a subset of patients, we evaluated the predictive value of progranulin (PC-derived growth factor/GP88). Progranulin levels have previously been shown to correlate with resistance to trastuzumab in tumor cell lines [25] . We studied the concentration of progranulin in serum samples before the start of XT or HXT treatment and after therapy, and correlated this with pCR.
statistics
The Simon minimax design was used with separate statistics for HER2-negative and HER2-positive cohorts. In the HER2-negative cohort, target accrual for the first stage was 34 patients. If more than five responses (15%) were observed, accrual continued up to a total of 53 patients. If the pCR rate was <15%, further evaluation was considered unjustified. The a and b values were both set at 0.1. In the HER2-positive cohort, target accrual was 19 patients. This was subsequently expanded to 50 patients to gain more information on the efficacy of HXT.
The primary end point was the rate of pCR, defined as no residual invasive tumor in breast and axilla (except for residual in situ carcinoma of the breast). Secondary end points included clinical response rate (based on RECIST after the third and sixth cycles), dose intensity, tolerability, diseasefree survival, and overall survival. All patients who received at least two cycles of therapy were evaluable for response. 4-54.8) . A conservative approach was adopted, whereby nonevaluable patients were counted as nonresponders. Five patients were considered nonevaluable: one had progressive disease during chemotherapy, three received 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) following XT(H) and were therefore not evaluable, and one refused surgery and had radiotherapy alone. When these patients were excluded from the analyses, the pCR rates were almost identical to those in the ITT population: 15.4% with XT and 43.5% with HXT. Analyses of pCR rate according to estrogen and progesterone receptor status and tumor size are shown in Table 2 , together with clinical response rates. After neoadjuvant therapy, 50 patients in the XT arm and 45 in the HXT arm underwent surgery, which was breast conserving in 9 (17%) of the 53 patients treated with XT and 8 (16%) of the 50 patients receiving HXT. The remainder underwent mastectomy.
By July 2009, distant relapse had occurred in six patients (11%) in the XT arm (three patients with bone metastases, one with visceral disease, one with mixed metastases, and one unknown). Three patients (6%) treated with XT had experienced local relapse in the same quadrant. In the HER2-positive (HXT) cohort, there had been five distant relapses (10%; bone in two patients, mixed metastases in two patients, and 'other' in one patient). Three patients (6%) receiving HXT had experienced local relapse in the same quadrant. At the time of this analysis, 40 patients (75%) in the XT cohort and 43 (86%) in the HXT cohort remained alive and relapse free (Figure 1 ). Seven patients in the XT cohort and five in the HXT cohort had died; overall survival is shown in Figure 2 .
treatment exposure
The majority of patients (81% in the XT arm and 88% in the HXT arm) received all six planned cycles of neoadjuvant Six patients were protocol violations for inclusion criteria: the HXT arm included three patients (6%) with stage IIB disease and two patients (4%) with stage IV disease (both of whom had contralateral axillary adenopathies but no other distant metastases); the XT arm included one patient (2%) with stage IIB disease. safety Safety data are shown in Table 3 . The most common adverse event was diarrhea/mucositis, which occurred in 79% of patients. However, most cases were mild or moderate. There was only one grade 4 episode of diarrhea/mucositis (in a patient receiving HXT); the grade 3 incidence was 30% with XT and 18% with HXT. Grade 3 hand-foot syndrome was observed in 11% of patients receiving XT and 6% of those treated with HXT. One patient in the HXT arm died from a perforated stomach ulcer during chemotherapy. None of the patients receiving HXT developed cardiac failure and there were no trastuzumab discontinuations because of cardiac toxicity.
biomarker analysis
Serum samples were available before and after chemotherapy (after the third and sixth cycles) in 31 patients. In the XT control group (n = 20), 3 patients achieved pCR, 1 had near pCR, and 16 had no pCR. In the HXT group (n = 11), 6 had 
conclusions
These results indicate that neoadjuvant XT combination therapy (with trastuzumab in HER2-positive disease) is highly effective in patients with inoperable LABC, demonstrating pCR rates of 15% with XT and 40% with HXT. The safety profile was consistent with previously reported studies evaluating capecitabine doses <1000 mg/m 2 twice daily. A nonanthracycline-containing regimen offers obvious benefits in the early breast cancer setting, where avoidance of long-term cardiotoxicity is more important than in the palliative setting. Furthermore, in HER2-positive disease, the option of a nonanthracycline regimen with trastuzumab is of clinical interest, particularly in those at increased risk of cardiotoxicity. An exploratory biomarker substudy did not support the hypothesis that serum concentrations of progranulin correlate with resistance to chemotherapy and/or trastuzumab in LABC (either HER2 negative or HER2 positive), but numbers are too small for definitive conclusions to be drawn.
The patient population in our study is noteworthy. We enrolled patients with 'true' locally advanced disease (cT4 or N2-3). The majority of studies reported in the literature include patients with smaller tumors. Patients with inoperable disease have a poorer prognosis [26] and the optimal treatment of these patients has not been defined.
Limitations of our study include the lack of a control arm and the relatively short follow-up. Although superficially our study resembles the XeNA trial conducted by US investigators [27] , there are several differences in the methodology, including duration of treatment (six cycles in our study versus four in XeNA), docetaxel schedule (day 1 and 8 every 3 weeks versus day 1 every 3 weeks), capecitabine dose (900 versus 825 mg/m 2 twice daily), patient population (inoperable breast cancer versus T2-3, N0-1), and primary end point (pCR rate versus rate of pCR or near pCR). The pCR rate (excluding near pCR) in HER2-negative disease was considerably higher in our study than in the interim analysis of XeNA (15% versus 9%), within the limitations of such a cross-trial comparison [16] . In HER2-positive disease, the corresponding pCR rates were 40% and 36%. The pCR rate we observed in HER2-negative disease in our study compares favorably with the range of 6%-14% reported with neoadjuvant anthracycline-taxane combination regimens [28, 29] .
In our trial, comparison of the efficacy of study therapy in the HER2-negative and HER2-positive cohorts suggests that the negative prognosis of HER2-positive tumor status is more than compensated for by treatment with trastuzumab. This is consistent with the findings from the ABCSG-24 trial, which demonstrated pCR rates of 40.5% in patients receiving trastuzumab-containing therapy for HER2-positive disease versus 27.7% in those with HER2-negative disease receiving chemotherapy alone [30] . Furthermore, in the NOAH trial, which was designed to determine whether the efficacy of chemotherapy was improved with neoadjuvant and adjuvant trastuzumab in patients with HER2-positive LABC or inflammatory breast cancer, event-free survival was significantly improved in the trastuzumab-containing arm (hazard ratio for 3-year event-free survival: 0.59; P = 0.013) [31] .
Since completion of our trial, data from two large phase III trials have become available. In both trials, the primary objective was met. The recently published FinXX phase III trial demonstrated that the incorporation of capecitabine into an anthracycline-and taxane-containing regimen significantly improves recurrence-free survival [12] . Patients receiving a regimen of XT (capecitabine 900 mg/m 2 twice daily, days 1-15, plus docetaxel 60 mg/m 2 , day 1) for three cycles followed by the combination of capecitabine, epirubicin, and cyclophosphamide for three cycles (XT / CEX) experienced significantly superior recurrence-free survival compared with those receiving single-agent docetaxel followed by sequential 5-FU, epirubicin, and cyclophosphamide (T / FEC). The hazard ratio was 0.66 favoring the capecitabine-containing regimen (P = 0.020). In the neoadjuvant setting, the large, randomized, multicenter ABCSG-24 phase III trial demonstrated a statistically and clinically significant improvement in pCR rate when capecitabine was added to epirubicin and docetaxel (TEX) (24% with TEX versus 16% with epirubicin and docetaxel alone) [2, 30] . The odds ratio for pCR was 0.58 (P = 0.02).
In contrast, the neoadjuvant GeparQuattro trial showed no difference in pCR rate between the capecitabine-and the non-capecitabine-containing treatment arms [32] . A possible explanation for the different findings is the timing of capecitabine administration in GeparQuattro; in the two positive trials, capecitabine was given upfront and for all six cycles, whereas in GeparQuattro, patients first received four cycles of epirubicin and cyclophosphamide before randomization to four cycles of docetaxel alone, XT, or original article Annals of Oncology docetaxel followed by four cycles of capecitabine. The shorter and later exposure may have contributed to the lack of effect of capecitabine.
Of particular relevance to the present study, an exploratory subpopulation analysis of GeparQuattro according to T stage revealed that among patients with cT4d, pCR rate was significantly higher with the capecitabine-containing regimens (34% with XT, 19% with sequential capecitabine / docetaxel, and 4% with non-capecitabine-containing therapy; P < 0.01 for both comparisons versus control). Therefore, it may be that when given later in the treatment schedule and/or for shorter periods, the greatest impact of capecitabine on efficacy is seen in patients with large tumors and/or inflammatory breast cancer. Subset analysis of patients with cT4d tumors in our study demonstrated pCR rates of 9% with XT and 47% with HXT. Capecitabine is being evaluated in an extensive clinical trial program in early breast cancer, and these trials may elucidate the optimal timing and duration of capecitabine in neoadjuvant and adjuvant regimens and enable improved patient selection.
The role of XT in the neoadjuvant setting is under further evaluation in the NSABP B-40 randomized trial, which is also assessing bevacizumab in neoadjuvant anthracycline-and taxane-containing regimens. The sequence of therapy in NSABP B-40 resembles the FinXX-style regimen rather than the GeparQuattro sequence: XT is given upfront (for four cycles) and then followed by doxorubicin and cyclophosphamide (four cycles), with or without bevacizumab for the first 6 cycles of chemotherapy and for 10 cycles postoperatively. This sequence is supported not only by the FinXX trial findings but also by observations from the neo-tAnGo trial, which showed that a taxane-first sequence was more effective than taxane administered after the anthracycline component [33] , and accumulating data in the literature [34] .
To summarize, our study findings suggest that XT and HXT represent active nonanthracycline regimens for early breast cancer and in particular for patients with large inoperable tumors. Further refinement of capecitabine-containing regimens and identification of patients who benefit most from this approach is ongoing.
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